VALENCIA, Calif., Feb. 21, 2013 /PRNewswire/ -- SANGUINE
BIOSCIENCES, INC. ("Sanguine"), a biotechnology company empowering
patients in biomedical research, has announced the closing of its
seed financing round, led by INVENT Ventures and Heliant
Ventures.
Sanguine engages research subjects through social media and
non-profit advocacy, and schedules blood draws, which are then
processed into DNA, RNA, cells, plasma, and serum, to be used as
biomedical research materials at pharmaceutical companies and
research institutions. The company has developed the infrastructure
to provide research subjects with information on how their samples
were used, in order to ultimately increase trust and information
flow back to researchers.
"Sanguine has experienced significant growth since Q4 2012, both
in terms of revenues and number of research subjects. The
successful completion of the laboratory and regulatory
infrastructure allowed us the opportunity to open our doors to
research participants, both healthy, and diagnosed with an
ailment(s), and to researchers at numerous pharmaceutical companies
and academic institutions.
We plan to use the funds raised in the seed round to further
develop our internal infrastructure in order to safely and
efficiently collect, process, document, and store up to 1,000 blood
samples each month across the west coast. We are looking forward to
scaling up and providing researchers with the samples they need to
perform their investigations, while also providing patients with
the knowledge of how their samples have impacted Personalized
Medicine research." – Brian
Neman, CEO
"Sanguine is building products and processes that will
revolutionize personalized medicine research," said INVENT CEO
Bryce Knight. "We are thrilled to
support Sanguine and its exceptional team through their growth at
the forefront of multiple rapidly-growing markets."
"We are very happy to jointly lead this round of investment and
to be connected to a company at the forefront of its
industry. Sanguine's business model achieves that unique
harmony between placing the patient interests first while still
generating returns for all its stakeholders," said Heliant
Ventures Director Ben
Weiss. "Full credit to the hard-working Sanguine
team for reaching this important milestone and we look forward to
supporting the company to realize its exciting growth
potential."
About Sanguine BioSciences Inc.
Sanguine BioSciences
is a biotechnology company bridging the gap between patients and
researchers by providing transparency throughout the personalized
medicine R&D process. Sanguine collects and de-identifies
patient-derived data in the form of biospecimen and physician and
self-reported information. These data are generated and then made
available to researchers involved in drug and biomarker research
and discovery. (http://sanguinebio.com)
About INVENT Ventures
INVENT Ventures Inc. (OTC: IDEA)
is a publicly traded venture fund that builds and invests in
transformative technology businesses. INVENT primarily operates in
markets of digital media, consumer Internet, and social networking,
and has built six companies at various stages of development.
(www.invent.vc.)
About Heliant Ventures
Established in 2012, Heliant
Ventures is a venture capital fund backed by leading investors
across Asia and Australia. (www.heliantventures.com)
SOURCE Sanguine BioSciences, Inc.; INVENT Ventures, Inc.